Which of these two biotech giants is the better buy in 2020?
News & Analysis: Gilead Sciences
Are these stocks value traps or bargain buys?
These are the best dividend-paying drugmakers on the market.
Paying a decent yield is just one of the reasons these stocks could be good buys for the new year.
The gene editing company published a proof-of-concept for "smart" immunotherapies. The idea may catch on.
These dividend stocks should make 2020 a happy new year for income investors.
But the big biotech isn't a happy camper about its contribution.
AbbVie and Gilead Sciences are two outstanding dividend growth plays for 2020. Here's why.
Which stock wins in this battle of two big biotechs?
Gilead's decision to add Vascepa to an ongoing NASH study failed to grab much attention last week. But this development is quite intriguing for several reasons.